Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31084560 | 1.00 | ALOX5 (0.45) | ALOX5TRPV1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL22227191 | 0.92 | NPC1 (0.44) | ALOX5ALDH1A1SMN1; SMN2MAPTNPC1 | |
| SCHEMBL30874422 | 0.92 | NPC1 (0.44) | ALOX5ALDH1A1SMN1; SMN2MAPTNPC1 | |
| SCHEMBL22225987 | 0.90 | NPC1 (0.44) | ALOX5ALDH1A1SMN1; SMN2MAPTNPC1 | |
| SCHEMBL31750464 | 0.88 | ALDH1A1 (0.54) | ALOX5TRPV1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL29940141 | 0.88 | ALDH1A1 (0.54) | ALOX5TRPV1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL751823 | 0.88 | ALDH1A1 (0.54) | ALOX5TRPV1ALDH1A1SMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL2882146 | 0.87 | ALDH1A1 (0.53) | ALOX5TRPV1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL17957734 | 0.82 | GSK3B (0.49) | ALDH1A1SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL4290086 | 0.81 | MAPT (0.55) | ALOX5TRPV1ALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. | 2025-03-06 | — | — | US | disclosed |
| WO-2024254599-A1 | HPGD INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11891389-B2 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-12-26 | — | — | US | disclosed |
| EP-1803455-A1 | N-thiazol-2-yl-benzamide derivatives | H.Lundbeck A/S (DK) | 2007-07-04 | — | — | EP | disclosed |
| EP-1682129-B1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2007-02-21 | — | — | EP | disclosed |
| EP-1682129-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-07-26 | — | — | EP | disclosed |
| US-20060154974-A1 | N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | disclosed |
| WO-2005039572-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-05-06 | — | — | WO | disclosed |
| EP-0543997-B1 | DERIVATIVES OF METHOTREXATE WITH ANTIRHEUMATIC ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1999-12-08 | — | — | EP | disclosed |
| CN-1032858-C | Methylamino pterin derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1996-09-25 | — | — | CN | disclosed |
| US-5354753-A | Methotrexate derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0543997-A1 | NOVEL METHOTREXATE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1993-06-02 | — | — | EP | disclosed |
| CN-1059725-A | Novel methotrexate derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1992-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891389-B2 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | ALOX5 19/4885TRPV1 3806/4885ALDH1A1 145/4885 |
| US-20060154974-A1 | N-thiazol-2-yl-benzamide derivatives | ADORA2A, ADORA3, ADORA1 | ALOX5 1188/4885TRPV1 197/4885ALDH1A1 624/4885 |
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGS1 | ALOX5 19/4885TRPV1 3963/4885ALDH1A1 183/4885 |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | KCNJ11, KCNJ1, KCNJ8 | ALOX5 2125/4885TRPV1 36/4885ALDH1A1 2897/4885 |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | FOXM1, MDM2, FOXO1 | ALOX5 3177/4885TRPV1 3039/4885ALDH1A1 620/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | ALOX5 2372/4885TRPV1 4613/4885ALDH1A1 1320/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | ALOX5 4493/4885TRPV1 4850/4885ALDH1A1 1185/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | ALOX5 337/4885TRPV1 3458/4885ALDH1A1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.